Related Experiment Video
Updated: Mar 14, 2026
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat
Elena Piegari1, Rosa Russo1, Donato Cappetta1
1Department of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Abstract:
New strategies to prevent and early detect the cardiotoxic effects of the anticancer drug doxorubicin (DOXO) are required. MicroRNAs emerged as potential diagnostic, therapeutic and prognostic approaches in cardiovascular diseases. MiR-34a has a role in cardiac dysfunction and ageing and is involved in several cellular processes associated with DOXO cardiotoxicity. Our in vitro and in vivo results indicated that after DOXO exposure the levels of miR-34a are enhanced in cardiac cells, including Cardiac Progenitor Cells (CPCs). Since one of the determining event responsible for the initiation and evolution of the DOXO toxicity arises at the level of the CPC compartment, we evaluated if miR-34a pharmacological inhibition in these cells ameliorates the detrimental aftermath of the drug. AntimiR-34a has beneficial consequences on vitality, proliferation, apoptosis and senescence of DOXO-treated rat CPC. These effects are mediated by an increase of prosurvival miR-34a targets Bcl-2 and SIRT1, accompanied by a decrease of acetylated-p53 and p16INK4a. Importantly, miR-34a silencing also reduces the release of this miRNA from DOXO-exposed rCPCs, decreasing its negative paracrine effects on other rat cardiac cells. In conclusion, the silencing of miR-34a could represent a future therapeutic option for cardioprotection in DOXO toxicity and at the same time, it could be considered as a circulating biomarker for anthracycline-induced cardiac damage.
Insights
Inhibiting microRNA-34a (miR-34a) protects cardiac cells from doxorubicin (DOXO) cardiotoxicity by improving cell health and reducing damage. This approach may offer a dual benefit as a cardioprotective therapy and a biomarker for anthracycline-induced cardiac damage.
Area of Science:
- Cardiology
- Molecular Biology
- Oncology
Background:
- Doxorubicin (DOXO) chemotherapy can cause cardiotoxicity, necessitating new prevention and detection strategies.
- MicroRNAs (miRNAs) show promise as diagnostic and therapeutic tools in cardiovascular diseases.
- MiR-34a is implicated in cardiac dysfunction and doxorubicin-induced cardiotoxicity.
Purpose of the Study:
- To investigate the role of miR-34a in doxorubicin cardiotoxicity.
- To evaluate the therapeutic potential of inhibiting miR-34a in cardiac progenitor cells (CPCs).
Main Methods:
- In vitro and in vivo studies exposing rat CPCs to doxorubicin.
- Pharmacological inhibition of miR-34a using antimiR-34a.
- Assessment of cell vitality, proliferation, apoptosis, and senescence.
- Analysis of key target gene expression (Bcl-2, SIRT1, p53, p16INK4a).
- Evaluation of miRNA release and paracrine effects.
Main Results:
- Doxorubicin exposure increased miR-34a levels in cardiac cells, including CPCs.
- AntimiR-34a treatment improved the viability, proliferation, and reduced apoptosis and senescence in doxorubicin-treated rat CPCs.
- miR-34a inhibition upregulated prosurvival targets (Bcl-2, SIRT1) and downregulated pro-aging markers (acetylated-p53, p16INK4a).
- Silencing miR-34a reduced its release from CPCs, mitigating paracrine cardiotoxicity.
Conclusions:
- Pharmacological silencing of miR-34a offers a promising therapeutic strategy for cardioprotection against doxorubicin-induced damage.
- miR-34a can serve as a potential circulating biomarker for monitoring anthracycline-induced cardiac injury.
